Key Highlights

  • Enliven Therapeutics (ELVN) has a 14-day RSI of 21.1, an extreme oversold reading even by biotech standards.
  • ELVN has fallen from a peak of about $61.15 on Aug. 24 but remains up 190.7% year-to-date.
  • Short interest was 12% of shares outstanding with 9.0 days to cover as of Sept. 15.

Enliven Therapeutics (NASDAQ:ELVN) rose 1.8% pre-market to $45.98, but its 14-day RSI of 21.1 shows the cancer-drug developer is one of the most oversold biotech stocks in the market after sliding from its August peak. The stock is still up 190.7% this year, holds about $895 million of cash, and carries a Strong Buy rating with targets up to $82.

Enliven Therapeutics' 14-day RSI has fallen to 21.1, an extreme oversold reading. RSI measures the pace of recent gains versus losses on a 0 to 100 scale, and readings under 30 are oversold; a reading near 20 is extreme.

The pullback does not appear to be driven by bad trial news. Enliven's lead drug, ELVN-001, is a small-molecule kinase inhibitor for chronic myeloid leukemia (CML), and its Phase 1 data has been described as encouraging. Instead, the slide followed a wider-than-expected quarterly loss of $0.49 per share versus $0.39 expected and about $10.7 million of insider selling over three months. The company is also expanding into Graves' disease, a market cited at about $16 billion.

Enliven (ELVN) Lags Biotech Peers

In the broader session, ELVN fell 2.0% while peers rose: Amylyx gained 1.0%, Tarsus 0.7% and Organon 0.2%, for a peer median of +0.7%. The $0.92 move equaled about 0.4x the 14-day average true range of $2.24, and Volume of $33.85 million was below the typical $54.36 million. The stock traded between $44.81 and $46.52 and closed mid-range. The market Capitalization is about $3.3 billion.

ELVN Technical Levels: Oversold Above the 200-Day

ELVN trades below its 20-day Moving Average of $54.22 and its 50-day of $55.89, but well above its 200-day of $39.60. That means the long-term uptrend from this year's rally is intact, while the short-term trend has cracked.

RSI at 21.1 is extremely oversold. Biotech stocks with strong cash and no clinical setback often bounce hard from readings like this.

MACD is -2.88, below its -1.68 signal line. MACD measures momentum, and a reading below the signal line confirms the pullback still has force.

ADX is 37.6. ADX measures trend strength, and a reading this high shows the recent decline has been persistent, so a turn may take time.

First resistance is $48.06, then $52.97. The 200-day average near $39.60 is the major support level.

Cash-Rich Clinical-Stage Biotech

Enliven has no Revenue yet, a Return on Equity of -15.3% and 60 employees, but it holds roughly $895 million of cash, about $12 per share. That cushion funds development without an immediate need to raise money. Analysts rate ELVN a Strong Buy with an average target of about $73.90; Stifel is at $82, Goldman Sachs at $80 and Barclays at $78.

Peers Moving on This News